Tag
PHH-1V, a protein-based COVID-19 vaccine, is shown to be a safe and effective heterologous booster in adolescents, generating strong and lasting immune responses against multiple virus variants.
Fractional doses (one-fifth and one-half) of 17DD yellow fever vaccine demonstrate non-inferior immunogenicity and comparable safety to full doses in children aged 9–23 months, supporting dose-sparing strategies during vaccine shortages.
Two hemophilia A patients developed persistent high-titer FVIII inhibitors following AAV-mediated gene therapy with a bioengineered FVIII transgene despite prior extensive FVIII exposure.
This review synthesizes long-term immunogenicity data from a South African RCT comparing 1+1 and 2+1 infant PCV10 and PCV13 schedules. PCV13 1+1 schedules maintain durable immunity up to age 5, supporting schedule optimization in establishe
This review synthesizes phase 2 and 3 trial data demonstrating that the pentavalent MenABCWY vaccine is immunologically non-inferior and well tolerated compared with MenB-fHbp and MenACWY-CRM vaccines, offering a simplified, effective vacci
This study uncovers a novel DR5/Ligase 3 feedback mechanism that sustains immunogenicity and enhances immune checkpoint inhibitor response in mismatch repair-deficient colorectal cancer.
A Phase 1 trial confirms that the HeV-sG-V vaccine is safe and, when administered in a two-dose 100 μg regimen, induces high levels of neutralizing antibodies against both Bangladesh and Malaysia strains of the Nipah virus.
A multicentre phase 1 trial in healthy US adults found nOPV1 and nOPV3 were well tolerated and induced robust homotypic neutralising antibody responses with shedding profiles similar to Sabin monovalent OPV, supporting progression to phase
A multicentre phase 3 trial shows single‑ and multidose EuTCV (Vi‑CRM197) are immunologically non‑inferior to Typbar TCV in infants 9–12 months, with comparable safety and reactogenicity across ages — supporting WHO prequalification.
This study evaluates immune responses and HPV infection rates in Indian girls after receiving one, two, or three doses of the quadrivalent HPV vaccine, supporting WHO’s recommendation for two doses spaced at least six months apart.
In a randomized, placebo-controlled phase 1 trial in Uganda, a single intramuscular dose of ChAdOx1 RVF (adenovirus-vectored) was well tolerated and induced rapid T-cell responses and neutralising antibodies, supporting further evaluation o
A phase 1 trial of the rVSV‑vectored Lassa vaccine demonstrated dose-dependent transient reactogenicity, no vaccine‑related serious adverse events or hearing loss, and robust, durable humoral and cellular responses across doses and lineages
A booster dose of the hexavalent group B streptococcus conjugate vaccine (GBS6) administered approximately two years after the primary dose in healthy adults is safe and elicits robust, enhanced immune responses, promising for maternal immu
A novel live attenuated oral vaccine, CVD 1902, shows 73% efficacy against Salmonella Paratyphi A infection in a controlled human challenge model, offering promising protection with a favorable safety profile.
This study assesses the safety and immune response of an adjuvanted RSVPreF3 vaccine in adult allogeneic hematopoietic cell and lung transplant recipients, highlighting modest antibody responses but robust CD4+ T-cell activation, supporting
This phase I/II trial demonstrates that the live-attenuated intranasal RSV vaccine (RSVt) is immunogenic and well-tolerated in infants and toddlers, offering a potential new preventive option against RSV infection.
A phase 2 trial in South Africa shows that the M72/AS01E-4 TB vaccine is safe and immunogenic for virally suppressed, ART-treated HIV-positive adolescents and adults, supporting its potential to address a key unmet clinical need.
A phase 4 trial in The Gambia finds that maternal Tdap-IPV vaccination is safe and provides early infant protection, but modestly blunts immune responses to whole-cell pertussis vaccines without compromising overall immunogenicity.
